| 183.4 1.43 (0.79%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 216.38 | 1-year : | 252.73 |
| Resists | First : | 185.25 | Second : | 216.38 |
| Pivot price | 173.3  |
|||
| Supports | First : | 162.44 | Second : | 148.33 |
| MAs | MA(5) : | 181.99 |
MA(20) : | 168.52 |
| MA(100) : | 153.78 |
MA(250) : | 153.36 |
|
| MACD | MACD : | 7.6 |
Signal : | 6.3 |
| %K %D | K(14,3) : | 94.2  |
D(3) : | 96.5 |
| RSI | RSI(14): 75.7 |
|||
| 52-week | High : | 185.25 | Low : | 125.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BDX ] has closed below upper band by 16.3%. Bollinger Bands are 116.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 184.03 - 184.76 | 184.76 - 185.39 |
| Low: | 179.19 - 180.1 | 180.1 - 180.89 |
| Close: | 181.84 - 183.31 | 183.31 - 184.59 |
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Sat, 15 Aug 2026
90,788 Shares in Becton, Dickinson and Company $BDX Acquired by Oppenheimer Asset Management Inc. - MarketBeat
Sat, 15 Aug 2026
Bryn Mawr Trust Advisors LLC Purchases Shares of 46,332 Becton, Dickinson and Company $BDX - MarketBeat
Sat, 15 Aug 2026
555,953 Shares in Becton, Dickinson and Company $BDX Bought by Everett Harris & Co. CA - MarketBeat
Fri, 14 Aug 2026
Becton Dickinson (BDX) CEO exercises 43,278 SARs and disposes shares under 10b5-1 plan - stocktitan.net
Fri, 14 Aug 2026
Why Is Becton Dickinson (BDX) Getting Fresh Attention Today? - simplywall.st
Thu, 13 Aug 2026
Becton, Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 272 (M) |
| Shares Float | 274 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 101.9 (%) |
| Shares Short | 10,380 (K) |
| Shares Short P.Month | 7,280 (K) |
| EPS | 5.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 88.84 |
| Profit Margin | 4.1 % |
| Operating Margin | 15 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 6.6 % |
| Qtrly Rev. Growth | -9.5 % |
| Gross Profit (p.s.) | 39.97 |
| Sales Per Share | 82.52 |
| EBITDA (p.s.) | 23.45 |
| Qtrly Earnings Growth | -31.4 % |
| Operating Cash Flow | 3,260 (M) |
| Levered Free Cash Flow | 4,620 (M) |
| PE Ratio | 31.73 |
| PEG Ratio | 1.1 |
| Price to Book value | 2.06 |
| Price to Sales | 2.22 |
| Price to Cash Flow | 15.32 |
| Dividend | 1.04 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|